Journal
PANCREAS
Volume 46, Issue 6, Pages 707-714Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPA.0000000000000850
Keywords
NANETS; medical management; neuroendocrine tumor; midgut NETs
Categories
Funding
- Advanced Accelerator Applications
- Novartis
- Guerbet LLC
- BTG International
- Lexicon
- Ipsen
- Merck
- Thermo Fisher
- Esanex
- BTG
Ask authors/readers for more resources
There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patientswith refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated Lu-177-DOTATATE in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available